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Abstract
Smart drug delivery system (SDDS) is a recently emerging therapeutic approach, now
turning into a conventional model to deliver drug to specific sites or target. Drug tar‐
geted (DT) delivery systems maintain the concentration of the drugs at desirable
doses in the body and avoid the need for repeated doses. The DT delivery system
have specific distinguishing features such as self-regulated, pre-programmed, multi-
targeted, controlled by timely response, monitoring of the targeted drug delivery, re‐
sponsive to pH, and spatially targeted. The DT delivery system exploits the biological
membrane changes in the physiology of malignant cells to increase absorption or en‐
try of drug-coated nanoparticles into targeted tissues. This system delivers a certain
quantity of a therapeutic drug for longevity of its action to a targeted area within the
human tissue, which in turn enhances efficacy of the treatment by reducing the side
effects of drug administration. A new DT therapy strategy is a health improvement
technique used in future generations for treatment of genetic diseases and intelligent
drug delivery. The ultimate goal of SDDS is to administrate the drugs at the correct
time with an exact dose in the body and with efficiency and specificity to the targeted
cells that help the patients better adhere to their therapy regimen. The DT system en‐
hances the maintenance of drug levels in targeted tissues and plasma without any de‐
struction to the healthy tissues. This DT delivery system uses various strategies in
targeting cells, drug delivery mechanisms, properties of targeted drug, organ-based
targeted sites, disease, and drug-targeted vehicles. This chapter deals with all aspects
of drug targeting and provides an overview of approaches in drug targeting, drug de‐
livery vehicles, and strategies involved in successful delivery.
Keywords: Smart Dug Delivery System (SDDS), drug targeting strategies, nanoparticles,
nanocarriers, passive and active targeting, folate receptor targeting, antibody targeting,
glycoprotein targeting, drug delivery, malignant cells
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1. Introduction
Smart drug delivery system (SDDS) is an advanced method of Drug Targeted (DT) delivery.
The smart drug delivered by this system must fulfill the following criteria: 1) increase the doses
of delivered drug to targeted body part of interest (tissue/cells/organs), 2) not be degraded by
any of the body fluids, 3) diminish side effects by improving the efficacy of drug treatment, 4)
absorption of the delivered drug must cross a biological membrane, and 5) drug is released in
appropriate dosages to the body part of interest. The ultimate goal of a DT delivery system is
to localize, maintain drug properties, ensure a specific route taken for the delivery of the drug,
target the desired site only, reduce side effects of the drugs, and prolong drug interaction with
the diseased tissue. Targeted delivery system maintains the required concentration of the drug
in plasma and tissues at the targeted sites, therefore, evading damage to normal tissue/cells
induced by the drug. The DT delivery system is highly complex and involves an integration
of various disciplines, such as biology, chemistry, and engineering [1–3].
Nanoparticle-based drug delivery systems are framed according to specific properties of target
cells, transport carrier/vehicles, nature of markers involving dug binding to specific ligands,
and receptor being modulated by physical components. Superlatively, DT delivery systems
should be non-immunogenic, non-toxic, chemically and physically stable in in vitro as well as
in vivo conditions, have restricted drug distribution to target tissue/cells/organ, have uniform
capillary distribution, have predictable and controllable rate of drug release, and have minimal
drug leakage during transit [3–5]. Carriers used for targeted drug delivery should be easily
bio-degradable or freely eliminated from the body without producing any side effects. The
preparation of the targeted delivery system should be stress-free or reproductive, reasonably
simple, and cost effective. The disadvantages of conventional drugs make attractive the
reasons to concentrate our efforts on targeted delivery. Conventional drugs have less solubility
of the given drug doses, poor absorption, shorter half-life, require large volume of distribution,
less specificity, and less therapeutic index, all these are significantly overcome in the targeted
drug delivery system [1–3].
In this chapter, we address: 1) the types of nanoparticles used internally for targeted drug
delivery system based on their size, shape, and materials (metal, biological, polymers, and
lipid); 2) specifically illustrate the mechanism and strategies of targeted drug delivery systems;
3) introduce the mechanism of organ-based targeted drug delivery system; 4) explain the
therapeutic strategies of drug delivery and targeting action; 5) elucidate the significance and
desirable properties of targeted delivery; 6) and finally, we validate a brief outlook of future
challenges and trends in drug targeted delivery systems that will be established to progress
their therapeutic efficiency and efficacy of drug functionality in future treatment of cancer and
genetic disorders.
2. Strategies of Targeted Drug Delivery Systems
Drug-targeted delivery increases the therapeutic efficacy by controlling the toxic effects
associated with the drug. Delivery of drugs to malignant tissue is increased and the normal
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tissue remains unaltered. The approaches of targeted drug delivery systems such as passive,
active, dual, combination, inverse, double, and physical targeting are being used extensively
in therapy.
2.1. Passive Targeting System
Passive targeting refers to the accumulation of a drug-carrier system or drug targeting at a
precise site; it may be attributed to chemical, physical, pharmacological, and biological aspects
of the disease. The nanoparticle size and surface properties of the drug targeted system must
be specially controlled to evade uptake by the reticulo-endothelial system to maximize the
targeting capability and increase its circulation. Rapid vascularization assists fast-growing
tumor tissue, imparting itself to a defective or leaky architecture enhancing the permeability
of toxic chemotherapeutic drugs. Few drugs can be administrated as inactive drugs or
prodrugs, hence, its exposure to cancerous tissue can be modified into highly active form.
Passive targeting also integrates targeted drug delivery to the malignant bed through various
invasive modalities.
2.1.1. Leaky Vasculature
Polymer nanoparticles exhibit the enhanced retention and permeability effects on targeted
delivery in tumor cells [6]. Capillary endothelium in tumor tissue is disorganized and enhances
the permeability towards macromolecules than normal tissues. This phenomenon allows
extravasation within the tumor interstitium to the polymeric nanoparticle circulating for
targeted drug delivery. The tumor bed lacks lymphatic drainage and results in drug accumu‐
lation, enhancing targeted strategies. A chemotherapeutic drug is linked with a specific
nanoparticle or nanocarrier by a linker that has the potential of augmenting the concentration
of therapeutic drugs within the malignant cells. These characteristic features (polymer-drug
conjugates) modulates the drug concentration in malignant tissue levels 10 to 100 times more
than free drug.
2.1.2. Tumor Microenvironment
The targeted drug is conjugated to a cancer-specific molecule and administered in an active
state. When it reaches its final target, the cancerous environment modulates the dug to a
volatile and active substance, the so-called malignant cell-activated prodrug therapy. Malig‐
nant tissue is characterized by vascular disorganization, intermittent basement membrane
alteration that stimulates the metastasis of atypical cells to normal cells. Insufficient supply of
nutrients and modulation of lymphatic networks does not remove the waste products in the
cells accurately. A tumor cell retains increasing concentration of protons and leads to a decrease
in the physiological pH of the cells [7]. The components of the extracellular matrix such as
macrophages, fibroblasts, and collagen fibers in the cancerous tissues are also elevated. The
degradation of tumor bed membranes and the extracellular matrix are enhanced by Matrix
metalloproteinase-2. A recent study about a water-soluble maleimide derivative of doxorubi‐
cin incorporating a matrix metalloproteinase-2-specific peptide sequence by Mansour et al. [8]
demonstrated (proved/showed) that this drug conjugate-polymer complex had a high affinity
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to cysteine-34 of circulating bound form of albumin. Doxorubin was efficiently cleaved by the
matrix metalloproteinase-2 from the bound form of albumin. The redox potential and modu‐
lated pH have been exposed as drug release triggers at the tumor site [9] for targeting.
2.1.3. Direct (Local) Drug Application
Direct application of the drug to the cancer cells permits the drug to react directly with the
malignant cells without systematic blood circulation. Various methodologies have been used
to improve the anticancer drug for targeted delivery for tumors such as intraperitoneal,
intravesical injection, and administration of various chemotherapeutic agents. These method‐
ologies require introducing higher concentrations of anticancer agents that is not always
possible. Localized targeted drug delivery by intratumoral direction is a modified and
attractive methodology, which has been used and tested [10]. Localized administration of
anticancer drug mitomycin surface of the malignant tissue leads to an increased concentration
of the drug and decreased toxicity at the targeted tumor site [11]. Onyx-0115 is a type 2/5
chimeric adenovirus improved by attenuation of the E1B-55 kDa gene [12]. Its complex with
some other proteins binds and inactivates the p53 gene. This drug has been administered by
various methods, most of which permit the drug to be applied directly into the malignant cells.
Onyx-0115 is used in clinical trials through intratumoral administration to treat head and neck
cancer [13], intratumoral via endoscopic ultrasound for pancreatic cancer [14], via hepatic
artery for metastatic colorectal cancer [15], intraperitoneal (IP) administration in ovarian cancer
[16], and intratumoral under radiographic guidance for advanced sarcomas [17]. Recently, a
polymer, poly (lactic-co-glycolic acid), linked with Tacrolimus (FK506) entrapped in pH-
sensitive microspheres [18] was administered rectally or orally to colitis animals. The experi‐
mental animals showed the released nanoparticles and drug concentration into the tumor
environment was different from its surrounding tissues. The drug permeability level in
malignant tissues was 3-fold higher than normal tissue when nanoparticles were used as drug
carriers. Direct targeted delivery of antitumor drugs into the malignant tissue inhibited the
drug from circulating in the blood. The drawback of direct targeted delivery of drugs into the
tumor is highly invasive and localization in some type of tumors is not feasible and can be
problematic.
2.2. Active Targeting System
“Active targeting” means specific interactions between drug/drug carrier and the target cells,
commonly through specific ligand-receptor interactions [19–23]. The ligand and receptor
interactions are possible only when these components are in adjacent proximity (<0.5 nm).
Specific ligand-receptor interaction for intracellular localization occurs after extravasations
and blood circulation. Active targeting is favored as it controls a drug carrier/drug toward a
target site (e.g., cruise missile). PEGylation increased the blood circulation time by altering the
surface of the drug carrier with poly (ethylene glycol) and/or improving the enhanced
permeability and retention (EPR) effect to augment the drug delivery to the targeted tumor
site. Earlier reports show that targeting tumor ligands does not result in augmented accumu‐
lation of the nanoparticles in targeted tumor sites. The specific molecules in tumor cells or
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intracellular organelles enhance the active targeting pathways needs to active delivery of the
drug into the entire tumor site [24–26]. Targeting a drug to a tumor site/specific area not only
enhances the efficacy of therapeutic drugs, it also reduces the toxic effects associated with the
drug and allows lower dosage of the drug for therapy. Active targeting is categorized into
three approaches, these are: 1) targeting and restricting the circulation of nanoparticles to the
capillary bed of a determined tumor targeted cell, site, tissue, or organ (cerebral ventricles,
peritoneal cavity, compartmental targeting in lymphatics, plural cavity, joints, and eyes); 2)
targeted delivery of the drug to a specific type of malignant cells/tissues and not to the normal
healthy cells (specifically delivery of the nanoparticles to kupffer cells in the liver); and 3)
targeting of nanoparticle delivery exactly to the intracellular site of targeted tumor cells
(receptor-based ligand enters into a cell by endocytosis). The third approach is highly favored
and used in guiding nanoparticles for targeted delivery through carbohydrates, receptors, and
antigens.
2.2.1. Carbohydrate Targeted
The cell surface of the carbohydrates disturbs the tumor cells' communication with normal
healthy cells or with the extracellular matrix through metastatic growth and spread. This
communication between the cells can be mediated through tumor cell binding proteins and
their carbohydrates known as lectins. Endogenous lectins play an important role in the
immunity to identify the “foreign patterns” of the cell surface carbohydrates on cancer cells.
It clearly depict that lectins disturb the survival of malignant cells, endothelium adhesion/
extracellular matrix, and tumor tissue vascularization processes that play a key role for
metastatic growth and spread [27, 28]. This carbohydrate-ligand bonding communication can
be made by improving the nanoparticles enclosing carbohydrate moieties focused on targeting
certain lectins (direct lectin targeting Consequently, targeted drug delivery systems have been
established based on this unique interaction/communication between lectins and carbohy‐
drates targeted towards whole organs [29] and may be dangerous to normal healthy tissues.
This is a major drawback of lectins, it should be rectified for the development of ‘‘smart carrier’’
molecules for targeted drug delivery. Lectin possesses a unique affinity for sugar moieties
present on the surface of cancer tissues. Thus, unique characteristic features seem to be an
attractive tool for further augmentation of nano-drug targeted delivery.
2.2.2. Receptor- and Antigen-directed Targeted
Human cancer cells overexpress the receptors or antigens on their surface that enhances the
efficient uptake of nanoparticles through receptor-mediated endocytosis, by which extracel‐
lular particles may enter into the intracellular environment. In general, drug-coated nanopar‐
ticles can enter into to the targeted tumor cells through ligand-receptor interactions. Once it
reaches the localized area of the tumor cell surface, the targeted drug-coated nanoparticles
may exert cytosolic action either after internalization or at the plasma membrane. Detachment
of the drug from its carrier can occur at the cell surface, extracellular space, or more promi‐
nently, in lysosomes by lysosomal enzymes ensuing in the release of the drug alone (without
carrier molecule) into the cytosol [30]. After the completion of drug delivery, the antigens or
receptors should be reprocessed back to the cell surface. Therefore, this form of targeted drug
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delivery contains essential molecules such as a nano-carrier to which targeted drug can be
conjugated and to which ligands-antibodies are conjugated, and enhances the high affinity to
the tumor cell surface, antigens, or receptors, respectively.
2.3. Dual Targeting System
The targeted drug delivery system is activated by stimuli, such as temperature, pH, redox, etc.,
some type of malignancies possess two stimuli around the tumor targeted environment at the
same time. Alteration by reduction in extracellular pH [31] and slight rise in local temperature
[32] would be more favorable for guiding drug delivery carriers that resort to two or more
external stimuli concurrently. However, emerging dual or multi-stimuli approachable
nanocarriers for tumor targeted therapy remains a great challenge. Nowadays, smart drug
targeted delivery system are drawing our attention toward thermo- and pH-sensitive activated
drug targeted delivery system. Various hyper-branched polymers that have the ability of
amalgamation of dual stimuli [33, 34] have been produced, and may be reasonable applications
in various malignancies. Furthermore, drug targeted delivery systems retaining sensitivity for
dual stimuli have also been designed. An earlier study by Wu et al. [35] examined the release
of 10-hydroxycamptothecin from dual stimuli-sensitive nanoparticles. Intestine-targeted
hydrogel coated with vitamin B2 accomplished by both thermo and pH stimuli-sensitive
developed by Liu [36] validated that noticeable thermo and pH sensitivity are suitable for drug
targeted site-specific nanocarrier in the intestine. Furthermore, thermo-sensitive hydrogels,
pH-sensitive polymers [37], enzyme-degradable, redox dual responsive micelles, and high-
intensity focused ultrasound (HIFU) [38], have also been designed to sustain the release of
drug targeted delivery system. Thus, precise information of the dual sensitive system was not
well established, but it provides an alternative for effective targeted drug delivery in biomed‐
ical applications.
2.4. Inverse Targeting System
Drug targeting attempts made to evade the passive uptake of the colloidal carrier by reticu‐
loendothelial systems are referred to as inverse targeting. The normal function of reticuloen‐
dothelial systems is blocked by pre-injecting macromolecules such as dextran sulphate or
blank colloidal carriers. This targeted methodology leads to the saturation of reticuloendo‐
thelial systems and the destruction of the defense system is used as an effective approach to
delivering targeted tumor drugs to non-reticulondothelial system organs. Colloidal-carrier
systems such as vesicle, micellar solutions, and liquid crystal and nanoparticle dispersions
comprising of small particles demonstrate the promise of great effects for targeted drug
delivery systems. The aim is to optimize the drug coating and releasing properties and
longevity of self-life of the drug with less toxic effects. The amalgamated drug with the
colloidal system involved in this modulation of microstructural system may impact molecular
interactions of the drug, which has mesogenic and/or amphiphilic properties [39].
2.5. Stimuli-Responsive/Triggered Drug Release Targeting System
Targeted tumor drug delivery systems are requisite to be biodegradable and nontoxic to
normal healthy tissue/cells and lethal and incisively dangerous to destroy the malignant cells.
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However, fast discharge of the drug from the nanoparticles may lead to premature release,
triggering systemic side effects; whereas, slow discharge may diminish the efficacy of the drug
at the targeted site of action and may enhance the action of multiple-drug resistance (MDR).
Hence, discharge of the drug for targeted systems should be in a well-organized manner at
the tumor targeted site. The design of stimuli-responsive drug carriers for targeted drug
delivery is highly preferred to augment the efficacy and bioavailability of the drug. Charac‐
teristic features of typical stimulus include temperature (thermal), pH, light intensity, magnetic
field, redox potential (i.e., enzyme), glucose (ionic strength specific stimuli such as concentra‐
tion of sugar moiety), and concentrations of electrolytes are used to localize the drug-nano‐
carrier to the determined targeted site. Responses of nanocarriers include precipitation/
dissolution, collapsing/swelling, hydrophobic/hydrophilic transition, degradation, bond
cleavage, and so on. Henceforth, we clearly state that external stimuli responding system
(magnetic field, light, and ultrasound) are of lesser impact, inexpedient and practically not
feasible (i.e., costs, scale-up product) than those of internal stimuli-responding systems
(temperature, pH, redox potential, etc.)
3. Organ-based Targeted Drug Delivery
The accumulation of the drug within a target area or tissue refers to targeted drug delivery
that is independent of the method for the targeted site and direction of drug administration.
A successful drug target delivery involves the following steps: appropriate proposed drug
coated nanoparticles must be circulated in the blood in concentration to ensure it reaches the
targeted site, the site must retain the nanoparticles, the release of the drug into the cells and
allowing enough time for effective mechanism of the drug. Targeted drug delivery to specific
sites in the human body requires unique delivery systems depending on the route selected.
4. Nanoparticles Used for Targeted Drug Delivery
Nanoparticles referred to as drug delivery vehicles or vectors are the most significant entity
necessary for the efficient delivery of the coated drug. A drug vehicle delivers and retains the
therapeutic drug to be transported to the site or in the locality of the targeted tissue or area.
These vehicles are capable of accomplishing specific functions that can be attributed to minor
modifications in its structure. An ideal vehicle must be selectively and specifically recognized
by the target site and should retain the functional specificity of the surface ligand without any
modification. It should be capable of crossing the barriers, stable in interstitial fluid and plasma
with non-toxic, non-immunogenic and biodegradable materials. Once the target cells recog‐
nize the carrier system, it must release the therapeutic drug moiety inside the anticipated
targeted site. We further discuss the properties and application of delivery vehicles in Table
1. Targeting principles of metal, polymer, lipid, and biological-based nanoparticles used in
therapeutics and promising direction in therapeutic research are discussed.
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Types and Description Properties Application Examples
Polymeric nanoparticles: Solid colloidal system
with drug in various forms either encapsulated,
adsorbed, etc. to form nanocapsules or
nanospheres
Highly biocompatible and
modifiable to make
nanoparticle conjugates, e.g.,
polymeric magnetic
nanoparticles,
polymersomes, polyplexes,
polymer hybrid system,
modifiable surface properties
High encapsulation of the
drug and drug protection,
prolonged drug delivery, and
long shelf life
Wide range of targeted
organs and cells,
N-2(hydroxypropyl)
methacrylamide
(HPMA) polymer most
widely used in
theranoustics
Polymeric micelles and
water soluble polymers
for improved drug
delivery
Synthetic
polymers such as
PLGA, LPLA,
PCL, and natural
polymers such as
Chitosan,
Gelatin,
Albumin,
Sodium Alginate
Dendrimers: Hyperbranched marcomolecules,
densely packed to the periphery till they reach
a "starburst effect"
Reduce viscosity of a
solution, densely packed
improved rheological
properties, outermost
dendrimeric surface can be
both polar or hydrophobic
capable or dissolving in
different solvents
Used as contrast agents
for MRI
Vectors in gene
therapy, soluble
dendrimers able to
solubilize acidic
hydrophobic molecules
and of fungus and
bacteria
PAMAM
dendrimer, PPI
dendrimer,
Techto
dendrimer,
Micellar
dendrimer
Inorganic
nanoparticles
Metallic Gold
nanoparticles
(GNPs):
Three shapes
of GNPs are
rods, shells,
and spheres
These have a unique
interaction with light, free
electrons undergo oscillations
in the presence of oscillating
electromagnetic field of light
Biosensors, especially
colorimetric biosensors,
for detection of
oligonucleotides
immunosensors and
redox enzyme
biosensing
GNPs are
conjugated with
Silica, PEG,
Chitosan,
platinum
tethered, gold-
SPION hybrid
Carbon-based
nanotubes:
Well-ordered
hollow
graphitic
nanomaterial
either single-
or multi-
walled
Possibility of both covalent
and non-covalent bonding
Site specific delivery of
proteins, peptides, nucleic
acids, and other drugs
Used as an imaging
agent
Applications in
malignancies of the
brain, blood, colon,
breast, liver, lymph
nodes, cervical, and
prostrate cancer
Multi-walled
carbon nanotube
(MWCNT)
Single-walled
carbon nanotube
(SWCNT)
Quantum
Dots (QD):
Uses the
Exceptional physical features
applied in optical imaging,
Unique optical features
for in vitro and in vivo
imaging especially
Multi-spectral
fluorescent
Imaging –
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Types and Description Properties Application Examples
bandgap
between
valency and
conduction
electron
bands,
exciton is
generated
due to the
difference in
absorption
energy and
the spectral
bandgap of
the core semi-
conductor
strong absorbance, bright
fluorescence
biomedical fluorescent
imaging, specifically
used in the study of
neuron and ganglia,
used in photodynamic
therapy especially to
treat lung and
gastrointestinal cancer,
accurate recognition of
molecular targets
Quantum Dots
(MSFI-QDs),
Carbon dots,
carbongenic-
QDs, Silica-QD’s,
Zinc oxide-QDs,
Metalloid Silica based
nanoparticles:
Silica particles
are good
materials for
nanoparticles
because of its
porosity and
surface
adaptability
Modifiable in size, porosity
and structure
Photophysical stability: does
not absorb visible or uv light,
biocompatibility, favorable
colloidal properties, high
porosity and extended
surface area, relatively
chemically inert, low cost of
production, easily prepared
and water dispersible
Application in
combined therapy as
they can transfer both
genetic material and
molecules of various
sizes. Used as an
optical contrast agent,
can conjugate with
antibodies, aptamers
and polymers
Solid silica-based
nanoparticles
(SiNPs),
Mesoporous
silica
nanoparticles
(MSNs)
Magnetic Iron oxide
magnetic
cores with
changing
shells are
used
Some forms of iron oxide
naturally occur in the body
(maghemite, magnetite), thus
reducing toxicity, various
bindings, and interactions
between the MNP and the
drug are possible such as
covalent, electrostatic,
encapsulation, and
adsorption
Used both in diagnosis
and therapy
concomitantly,
Liver and spleen
readily imbibe the
MNP and can also be
used in barin
malignancies and it is
able to cross the blood
brain barrier
Iron oxide cores
with shells of
gold, polymer,
dendrimers, and
silane
Biological Lipids Homolipids,
Heterolipids,
complex-
lipids
Increase in drug solubility,
pharmokokinetics properties,
reduced toxic effects
Applications in oral
drug delivery,
parenteral dug
delivery, peptide and
Solid lipid
nanoparticles
(SLN),
Nanostructured
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Types and Description Properties Application Examples
protein drug delivery,
nasal vaccination, etc.
lipid carriers
(NLC), Lipid
drug conjugates
(LDC),
Liposome,
transferosomes,
niosomes
Table 1. Types of nanoparticles, properties and applications in medicine.
4.1. Lipids-based Nanoparticles
Liposomes are small, artificially designed vesicles entirely surrounded by phospholipid
bilayer membranes with various size ranges (20 to 10,000 nm) [40]. Drug molecules are
encapsulated or intercalated into the phospholipid bilayers that extend the location of the drug
with physico-chemical nature of lipids. Recent study demonstrates that lipid DOX loaded
nanoparticles have potential effects on useful therapeutic targeted drug against adriamycin-
resistant breast cancer. Entrapped drug (chemical compounds) molecules inside the modified
liposomes (transferring [41] or antibody [42, 43]) cause apoptosis of tumor cells [41–43]. Solid
lipid nanocarriers can be commonly used for the treatment of chemotherapy resistant tumor
[44] to deliver the targeted drug.
Self-assembled, hydrophobic interactions of amphiphilic block copolymers (5–50 nm) form
supramolecular core-shell structures in aqueous solutions called micelles are gaining great
attention in targeted drug delivery applications. Pluronic, phospholipid, polyester, and poly
(L-amino acid) are the most often used micelles. Drug entrapped with block copolymer
micelles and transported at high concentrations can exceed their intrinsic water-solubility.
Furthermore, hydrophilic blocks form hydrogen bonds within the aqueous solution and form
a compact shell that covers the micellar core protecting it against hydrolysis and enzymatic
degradation with the help of hydrophobic core. Moreover, the reticuloendothelial system may
prevent the recognition of the corona and eliminate the polymeric micelles from the blood
circulation. The molecular weight, chemical composition, and block length ratios can be easily
changed that control the size and morphology of the micelles. The cross linkable group with
block copolymer can enhance the stability of the micelles and increase their temporal control.
Polymeric micelles can be linked with various ligands, such as epidermal growth factors,
antibody fragments, α-2-glycoprotein, folic acid, and transferrin, delivering the targeted
anticancer drug to the tumor tissues/cells by passive and active mechanisms. Most of the
anticancer drugs are poorly water soluble in nature, polymeric micelles deliver these anti‐
cancer drugs to the targeted tumor sites that selectively act only on targeted cells and do not
affect the normal healthy cells. However, most of the polymeric micelles have been successfully
established in targeted therapeutics and some are still at preclinical trials. Future studies need
to pave the way for these therapies into clinical practice to increase the survival rate of cancer
patients and enhance anticipation of cancer chemotherapy [45].
Smart Drug Delivery System40
Niosomes are defined as nonionic surfactant vesicles that entrap both lipophilic and hydro‐
philic drugs in the vesicular membrane/aqueous phase. These are made up of lipid material
possessing better stability than liposomes. Niosomes may be established as useful carriers for
targeting the drugs to treat tumor, viral, parasitic, and other microbial diseases more effec‐
tively. Pharmacosomes are self-assembling components consisting of a pharmocon (active
component) and a carrier molecule composed of amphipathic drugs. Drugs covalently linked
to lipid molecules may be in colloidal dispersion as micelles or as ultrafine hexagonal aggre‐
gates used in targeted therapy. Ufasomes are single-chain fatty acid surfactant vesicles formed
from double-chain amphiphiles and micelles. They are composed of lipid bilayer liposomes
made of single-chain unsaturated fatty acids used in targeted drug delivery. Ufasome vesicles
are colloidal suspensions of closed lipid bilayers consisting of ionized species (soap) and fatty
acid molecules composed of more amphiphiles than micelles. These readily available fatty
acids give ufasomes an advantage over liposomes. Cubosomes refer to liquid crystalline
liposomes formed into cubic nanoparticles that are suitable for injection at the targeted site.
Lipid droplets that allow easy penetration through the pores are called transferosomes, which
are smaller than a droplet. Transferosomes is a supramolecular entity that can pass via
permeability barriers and transport drug from one side to the other and is more elastic than a
liposome.
4.2. Biological-based Nanoparticles
In addition to micelles, some groups of nanoparticles forming self-assembling structure are
known as cell-penetrating peptides (CPPs). These molecules are applied in recognizing
hydrophobic drugs and delivering biomolecules such as nucleic acids (siRNA, pDNA)
intracellularly to the targeted cells. Furthermore, CPP drug delivery system is more construc‐
tive owing to its low toxicity, biocompatibility, structural stability, and easy preparation [46–
49]. Addition to hydrophobic interaction, CPPs improve the nucleic acid delivery system. Both
hydrophobic interactions and the electrostatic nature of CPPs contribute to its stable structure
that can easily enter into the cells and deliver the siRNA.
Proteins are also important and promising agents for drug delivery that bioconjugate with
drugs and deliver to the targeted sites (albumin-conjugated with paclitaxel named as abrax‐
ane). Albumin and paclitaxel linkage (abraxane) are prepared by homogenization under high
pressure [50]. However abraxane is a more effective and less cytotoxic drug compared to
conventional drugs. The drug is released from abraxane through the albumin receptor in blood
vessels of the tumor cells [50, 51]. Bioconjugation of albumin-paclitaxel combination has been
effectively used against lung cancer [50], breast cancer, [51] and gastric cancer [52].
4.3. Polymeric-based Nanoparticles
Polymers have good biocompatibility, are easily prepared, and morphologically manipulated
into a variety of designs and structures. They possess bio-mimetic properties making it a
widely used biomaterial. Polymers play an important role in smart drug delivery systems as
they can effectively deliver chemotherapeutic drugs directly into the targeted site. The surface
of polymeric nanoparticles has been functionalized by the alteration of nanoparticles through
emulsification, adsorption, polymerization, functional surfactants, modulation of various
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forms of bio-conjugation, and covalently-bound functional molecules. Polymers are widely
used in numerous therapeutic applications for targeting cancer, disorders of the central
nervous system (CNS), and other bacterial and viral infections. Zhang et al. [53] reported that
more than 26 nanoparticles based on their therapeutic action have been approved for clinical
trials and a few more are in the pipeline. Polymeric nanoparticles possess characteristic
properties that affect its bio-distribution, efficiently enhancing the delivery of targeted drug
across the blood brain barrier compared to conventional drug treatments as well as other well-
known drug carriers [54].
Microspheres are biocompatible polymers either particle or soluble in nature. Polymeric
backbone carriers are N-(2-Hydroxypropyl) methacrylamide (HPMA) prepared by ficoll,
dextrans, sepharose, or poly-L-lysine as core carrier system for chemotherapeutic drugs.
Microspheres (30–200 μm) are larger than nanoparticles (0.2–0.5 μm) but have a smaller area
for drug loading than soluble polymers. The drug incorporation of microsphere considerably
affects its release rate. Once the drug is administered or systematically transported, it rapidly
dispenses into the target site and is subsequently internalized by macrophages of the phago‐
cytic system. Moreover, microspheres and nanoparticles are mostly used for cell-selective
applications of drug delivery (oral delivery peptides and peptidomimetics) [55–58].
Dendrimers play a significant role in the delivery of different compounds such as tamsulosin,
primaquine phosphate, 5-fluorouracil, doxorubicin, tropicamide, indomethacin, artemether,
and pilocarpine as targeted drugs [59]. Bioconjugated dendrimers can deliver the targeted
drug transdermally, intravenously, orally, and through the ophthalmic route, which proves
the versatility and functionality of dendrimers [60].
4.4. Carbon-based Nanoparticles
The properties [61], application [62–68], and solubility nature [69] of carbon nanotubes are
well-established nanocarriers for drug delivery. Jain et al. [70] reported that chemical modifi‐
cation of carbon nanotubes by carbohydrate D-galactose can generate a novel cascade of
chemical functionalization of multi-walled carbon nanotubes (MWCNTs). Therefore, galacto‐
sylated MWCNTs are used to deliver the active ligands (such as galactose) as a bioactive(s)
targeted drug to the tumor site (hepatic tissues) [70].
Carbon nanohorns related to carbon nanotubes belong to a new class of carbon materials.
Single-walled carbon nanohorn (SWNH) aggregates consist of thousands of graphitic tubules
(2–5 nm in diameter, similar structure to single-walled CNTs) having a spherical structure (50–
100 nm in diameter). Based on the morphological features, nanohorns are divided into bud,
dahlia, and seed types. SWNHs are non-metallic catalysts produced by laser ablation of a pure
graphite target; however, its toxicity must be proactively investigated. Molecules completely
composed of carbon are fullerene, spherical fullerenes are known as buckyballs. Fullerenes are
similar to graphite structure consisting of stacked graphene sheets of connected hexagonal
rings and pentagonal rings. Fullerene C60 is highly biocompatible with reduced toxicity and
is used for targeted drug delivery for several diseases such as Parkinson’s and HIV.
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Nanoshells have a dielectric core covered with a thin metallic shell of gold-coated silica that
is spherical in shape. These are used for early stages of cancer detection and treatment. Injected
embedded drugs consist of cancer-targeted hydrogel polymers that are released at the tumor
targeted site when exposed to laser (infrared).
4.5. Metal-based Nanoparticles
Metal-based nanoparticles are fascinating because the metal exhibits an important electronic
and optical property and acts as an insulator or semiconductor [71–73]. Transition (Al, Co, Cu,
Fe, Ni, Ti) and noble (Au and Ag) metal nanoparticles reveal a luminescence emission in the
visible wavelength of light. Recent studies show metal linked with carbon nanotubets
(Ag/CNT composites) are gaining increased attention due to their potential applications as
optical limiters [74], catalyst [75], and advanced materials [76] capable of being used in bio-
imaging of the cancer cells for targeted therapy [74].
Targeted drug delivery with gold nanoparticles possess a unique chemical and physical
characteristic feature as they have strong binding interaction with proteins, thiols [77],
aptamers [78], carboxylic acid [79], and disulfides linkages. These are widely used in tumor
targeted delivery system for therapeutics. Gold particles can enter into targeted sites by
phagocytosis, fluidphase endocytosis, and receptor-mediated endocytosis [80], depending
upon the shape, size, surface charge, synthesis process, functionalized molecules, and surface
coating toxicity of gold. Moreover, gold nanoparticles are considered to be non-toxic agents
for drug delivery [81]. Gold nanoparticles possess a functional flexibility with prodrug
molecules by covalent or non-covalent linkage enhancing the efficient transport of the drug
into the targeted tumor sites. Gold nanoparticles can hold high drug concentration and deliver
it to the specific targeted site via various routes of drug administration. Conventional drug
side effects can be reduced by conjugated gold nanoparticles reducing the tumor survival rate.
5. Therapeutic Strategies for Drug Delivery
5.1. Folate Targeting
Folate receptors (FRs) are overexpressed in various tumors (including leukemia, endometrial,
ovarian, and kidney cancer), which binds vitamin folate and folate-drug conjugates with a
high affinity [82]. Folate receptors are targets of various therapeutic strategies aimed at efficient
delivery of chemotherapeutic drugs. Folate receptors also play a role in the uptake of antifolate
drugs that are used for therapeutic intervention in malignant disorders. The salient features
of folic acid for therapeutic strategies are: i) reasonable binding affinity to both diagnostic and
targeted therapeutic agents; ii) its unique and high affinity for the folate receptor, even after
binding to diagnostic and therapeutic cargo; and iii) the folate receptor in normal healthy
tissues have limited scattering, despite its overexpression on both type of tumors cells (FR-α
and FR-β isoforms) [83]. Earlier investigations [84] show that folate enter the cells through
receptor-mediated endocytic process. Hence, folic acid is repeatedly used as a drug targeting
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ligand coated with delivery vehicles (polymeric nanoparticles, liposomes, dendrimers, and
protein toxins) to selectively deliver targeted drugs into malignant cells.
We were the first to report that curcumin enhances the up-regulation of folate receptor β
mRNA and protein levels in KG-1 cells by modulating the uptake and cytotoxicity of metho‐
trexate. Notably, curcumin also augmented folate receptor β function as a transporter for
radiolabeled folic acid and methotrexate in KG-1 cells. These reports optimized curcumin
dosage and reduced the concentration of methotrexate resulting in the effective destruction of
tumor cells. Therefore, amalgamation of non-toxic concentrations of methotrexate and
curcumin may be a viable strategy for therapeutic intervention for leukemia using a folate
receptor-targeted drug delivery system [85]. Shen et al. [86] reported that folate receptor-
targeted drug conjugate had less communication with the cells and easily entered through
overexpressed folate receptor of malignant cells by receptor-mediated endocytosis. Later the
drug was transferred into lysosomes, wherein the active form of drug poly (amido amine)]
dendrimers (PAMAM) was regenerated. The PAMAM left the lysosome and released anti‐
cancer drug camptothecin (CPT) in the nucleus. This modulation creates PAMAM dendrimers
as valuable drug carriers for in vivo tumor cell nuclear drug targeted delivery. Folate receptor-
targeted (nanoparticles) delivery systems, despite showing significant promising effects in
human pathologies, enhance the tumor selectivity for tumor targeting. This modulatory
strategy avoids possible obstacles, and we anticipate that folic acid will act as an essential
candidate for receptor-targeted therapeutics in the near future.
5.2. Antibodies Targeting
Specific antigens are exclusively expressed on the surface of the cancer cells. Antibodies,
especially monoclonal antibodies (mAb), can be produced to identify and specially bind to the
antigens associated with tumor cells. In 1981, Milstein [87] developed an mAb that binds to
malignant cells, a few functional classes of antibodies that possessed more binding and
destroying activity in the tumor cells. Currently, numerous mAb-based tumor tissues targeting
therapeutics has been effectively translated into clinical treatment such as trastuzumab,
rituximab, cetuximab, and bevacizumab [88-91]. These mAb could be used as fragments or in
their native state, generally having higher affinity toward tumor-associated antigens depicting
its targeting efficacy. Moreover, the whole mAb are more beneficial than fragments to develop
a higher binding affinity, owing to a synergic effect of having more than one binding site.
Furthermore, the full or entire antibody sequences express more EPR effects that are main‐
tained in cancer tissues, while in small fragments express less EPR effects that can easily be
eliminated from blood circulation [92].
Recent investigations have attention on multi-functionalization of the nanoparticle surface
with specific mAbs and encapsulation of therapeutic drugs into nanoparticles to sustain its
targeting efficacy. Recent studies by Nobs et al. [93] shows poly-(lactic acid) (PLA) nanopar‐
ticles conjugated rituximab and trastuzumab exhibit six-fold enhances affinity and uptake
compared with similar particles without mAb targeting molecules. The investigation of
Miyano et al. [94] shows conjugated KG6Etrastuzumab (KG6E-amino acid dendrimer with
surface modified by sixth-generation lysine dendrimer with glutamate –KG6Etrastuzumab)
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was expressively internalized and then transferred to lysosome for human epidermal growth
factor receptor -2 (HER-2) positive cells (SKBR3), compared to HER2 – negative cells (MCF-7)
indicates that KG6E-trastuzumab conjugates act as HER-2 targeting carriers in drug targeted
delivery for cancer therapy. However, nanoparticles conjugated with mAbs still encounter
numerous tasks and boundaries, owing to a “binding-site barrier” (decreased rate of penetra‐
tion of nanocarriers due to high binding affinity) in solid tumors [95].
5.3. Glycoprotein Targeting
Serum glycoprotein transferrin (Tf) acts as a transporter to deliver the iron molecule into the
cells via blood by binding to the transferrin receptor successfully that is being internalized
through receptor-mediated endocytosis [96]. TfR is overexpressed on most of the tumor cells
such as colon, pancreatic, lung, and bladder cancer cells due to increased metabolic rates. The
TfR expression is 100 times greater in cancerous cells than normal healthy cells, this increase
in expression is a result of a higher demand for iron in tumor cells, essential for their survival
[97]. Tf has been often used as a drug targeting ligand in TfR-targeted drug delivery system
for tumor cells. Direct conjugations of nanocarriers to Tf have enhanced intracellular drug
delivery and efficient therapeutic outcome. Ishida et al. [98] demonstrated Tf conjugated with
polyethyleneglycol (PEG)-liposomes exposed over prolonged periods in blood circulation but
had reduced uptake via reticuloendothelial system (RES) in colon cancer. This proposes that
Tf-conjugated nanoparticles were internalized by receptor-mediated endocytosis owing to
specific ligand-receptor binding for cytoplasmic targeting to cancer cells. Tf-conjugated
paclitaxel coated with poly (lactic-co-glycolic acid) (PLGA) nanoparticles showed enhanced
suppression in cell growth than free paclitaxel in MCF-7 and MCF-7/Adr cells [99]. Doxoru‐
bicin (Dox)-coated, HAIYPRH (T7)-conjugated, PEG-modified polyamidoamine dendrimer
(PAMAM-PEG-T7/Dox) nanoparticles was fabricated by Jiang et al. [100]. This modified
targeted drug effectively accumulates in malignant cells via intravenous administration and
can be internalized into cancer cells with Tf. These studies proved that Tf acts as a ligand for
targeted drug delivery system in TfR overexpressed malignancies. However, TfR is also
expressed in normal fast growing healthy cells (epithelial, fibroblast, and endothelial cells) that
could lead to non-specific targeting and increase the cytotoxic effects reducing the efficacy of
the targeted drug [101]. Furthermore, Tf with nanoparticles targeting ligands may improve
drug delivery in tumor tissues and distribution in blood circulation similar to normal healthy
cells expressing TfR (non-targeted systems) [102].
5.4. Oligonucleotide Targeting
Short, single-stranded RNA or DNA oligonucleotides designed in vitro from a huge number
of random sequences around 1014–1015 that can identify the specific target sites are known as
aptamers [103]. Aptamers possess high affinity and specificity features enhanced to bind a
wide range of intracellular molecules, such as receptors, small molecule drugs, and proteins
[104] specified for aptamer-based targeted cancer therapy. Although, aptamers and mAbs have
similar and specific affinity against selected molecules, aptamers possess their own unique
features: they can be synthesized in vitro without laboratory animals [105] and nanoparticle-
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conjugated aptamers very efficiently target the tumor tissue via active targeting pathway.
Lupold et al. [106] established nanoparticle-conjugated aptamer (A10 aptamer) that target
overexpressed transmembrane protein of prostate specific membrane antigen (PSMA) in
various tumor tissues. Aptamers-doxorubicin (Apt-Dox) are conjugates that are also imple‐
mented (designed) for targeted delivery to malignant cells [107]. Furthermore, Huang et al.
[107] demonstrated that Dox conjugated to DNA apatamer-sgc8c (sgc8c-Dox conjugate) retains
its high binding affinity features increasing efficiency of internalization by tumor targeted cells.
These characteristic features make targeted delivery of chemotherapeutic drugs more feasible
with abundant targeting potencies. Furthermore, these therapeutic strategies give rise to a
novel targeted drug delivery and provide promising approaches for future treatment.
5.5. Membrane Protein Targeting/Cell Surface Receptors Targeting
Integrin membrane glycoproteins are heterodimeric in nature composed of non-covalent
bonding of α and β subunits; they play a major role in tumor malignancy and angiogenesis
[107]. In tumor endothelium αvβ3 and αvβ5, integrins are overexpressed at the highest levels.
Asparagine/glycine/arginine (NGR) and arginine/glycine/aspartic acid (RGD) are the largest
number of tumor-homing peptides used to detect the corresponding receptors of integrins αvβ3
on tumor endothelial cells. Brooks et al. [109] reported that RGD vascular homing peptides
enhanced intracellular targeted drug delivery accomplished via integrin-binding RGD and
suppress the tumor growth. Recent studies described Dox-coated nanoparticles with cyclic
RGD peptide ligand delivered the drug to targeted integrin αvβ3 and caused a decrease in
survival rate of the tumor cells [110]. Moreover, investigations on paclitaxel entrapped
liposomes with peptide consisting of specific ligand to alpha V integrins and specific motif to
neuropilin-1 showed significant increase in paclitaxel uptake in targeted tumor cells (A549 and
HUVEC) depicting the enhanced suppression of cell growth by dual targeted mechanism
compared with single-targeted paclitaxel entrapped liposomes and paclitaxel injections
(Taxol) alone [111]. Furthermore, investigations show that cyclic RGD peptide (cRGDyK)
conjugated in PEG-b-PLGA micelles deliver the targeted hydrophobic drug into intracellular
cancer cells and its neovasculature, enhancing the antiproliferative and cytotoxicity efficacy
compared with cRGDyK-free non-targeted micelles [112]. However, targeted delivery to
integrin glycoprotein meets many challenging tasks for therapeutic strategies. The most
common are integrins receptors, which are extracellular and expressed in normal fast growing
healthy epithelial cells other than tumor cells. Treatment with RGD also targets the normal
functional integrin (α5β1 and α4β1) molecules, thus resulting in targets of nonspecific tumor
cells [113].
6. Significant Role and Functional Properties of Targeted Drug Delivery
The application purpose of nanoparticles in nanomedicine is targeted drug delivery system
[114]. In the past two decades, scientists have developed and understood the mechanism of
drug delivery and drugs have been designed for targeted delivery s [3]. Most of the new and
currently available therapeutic drugs (95%) have poor biopharmaceuticals and pharmacoki‐
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netics properties [40]. Therapeutic index of efficiently biological targeted drugs must be
improved by suitable nanotechnological application for targeted delivery in tumor cells/
tissues. Nanotechnological approaches [114] enhance reconsideration of failed clinical trials of
chemotherapeutic drugs.
The targeted drug should be safe and effective with sufficient drug concentration in the body
to deliver an effective dosage at the targeted tumor site. Chemotherapeutic targeted drugs
must possess high toxicity and strong inhibition toward the targeted tumor tissue/cells
proliferation. Many researchers have demonstrated that biological toxins, protein macromo‐
lecules, hydrophobic, and hydrophilic drugs are delivered through nanocarriers. Nanostruc‐
tured designs are promising components that enable novel chemotherapeutic drugs for
targeted delivery and explain the principles of component-targeted drug delivery systems
(Figure 1). Nanomedicine has continuously released drug delivery mechanisms that enter into
the cell by intracellular mechanisms and reduces its side effects. Nanoparticles have greater
advantage than microparticles. They are appropriate for intravenous targeted delivery,
tremendously exploited for well-controlled targeted drug release at site-specific targeting,
have prolonged the time of blood circulation facilitating extravasation of drug delivery, and
have favorable outcomes in site-specific drug targeting for treating cancer as well as disorders
of the CNS and immunodeficiency infection [115]. Moreover, 300 pharmaceutical companies
in the United States (US) mainly focus on targeted drug delivery systems. Additionally, drugs
can be administrated through oral, pulmonary, ocular, transmucosal, and implantation routes
of delivery.
Figure 1. Schematic representation of components of targeted drug delivery
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Nanomaterials are used in targeted drug delivery including metal-, biological-, lipid-, silicon-,
carbon-, and polymer-based materials [114]. These technology-based medicines (nanomedi‐
cine platforms) can be multifunctional, also known as intelligent/smart drug system. We raise
awareness of the physiological and functional challenges of therapeutic application and
enlighten recent advances in our understanding and mechanism of tumor biology [116].
Nanoscale drug targeted delivery system is capable of enhancing pharmacokinetics and
increasing the bio-distribution of therapeutic agents to targeted organs/tissues/cells with
improved efficacy of the drug. The volume of drug distribution and toxicity is reduced, owing
to drug accumulation at specific targeted sites and reduced concentration in normal healthy
cells while using nanoscale carriers. It is designed to target cancer and inflammation sites
through permeable vasculature. It is also biocompatible and made of biodegradable materials
reported as safe replacement drug carriers than existing vehicles that may cause allergic
reaction and peripheral neuropathy [40]. Few drugs have a very short half-life in blood
circulation. The efficacy and stability of the drug can be increased by enclosing a drug with a
nanocarrier to extend its short-half life. For example, a drug can be enclosed with a nanosized
carrier (liposome).
Most of the drugs face difficulties in targeting tumor sites while crossing the blood brain barrier
(BBB). Nanoparticle-coated drugs potentially penetrate BBB and are shown to potentially
enhance the therapeutic concentration and index of anticancer drugs that have been deliv‐
ered to the brain tumor. Its most noteworthy advantage is reduced toxicity and enhanced efficacy
of the drug by guiding the drug to its target and retaining the drug concentration at the targeted
site for a longer duration to increase its therapeutic action. [114]. Figure 2 explains the desira‐
ble therapeutic strategies of smart drug targeted delivery systems. Solid tumors possess vascular
pores (vascular pore cut-off 380–780 nm) depending on various sizes, type of cancer, microen‐
vironments, and proliferation rate. Thus, drug with the carrier molecules should be smaller
than vascular pore cut-off size (diameter) to reach its targeted tumor sites. Normal healthy blood
vessels do not permit drug-associated carrier molecules larger than 2–4nm size compared with
unassociated  drug  molecules.  Thus,  nanomedicine  has  paved the  way to  enhance  drug
accumulation and its concentration in targeted cells/tissues/sites by extravasation and consid‐
erably diminishing its toxicity and distribution to normal healthy cells [40]. Ideal nanocarrier
materials  should be without any chemical  modification and must fulfill  the demands of
biocompatibility, biodegradability, and release dynamics of targeted drugs [117, 118].
Nanocarriers essentially need to prolong exposure time in blood circulation and allow the
nanocarriers to reach the targeted site through multiple pathways. Generally, nanoparticles
possess a very short half-life, owing to natural immune/defense mechanisms of the human
system that eradicate them after opsonisation by phagocytic mechanisms. Thus, the nanocar‐
rier surface must be altered to be invisible to the opsonisation process.
Nanocarriers are naturally made up of macromolecular materials or entrapped lipids,
adsorbed onto the surface of the nanoparticles or dissolved within the polymeric matrix. They
are categorized into two types: nanospheres (matrix systems used to dispersing drug mole‐
cules) and nanocapsules (vesicular systems drugs that are surrounded by a membrane).
Nanotechnology-based polymers are designed as top-down and bottom-up processes. The
top-down method is initiated by breaking down larger objects into nanostructured molecules
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by over grinding, etching, or ball milling enhanced by laser or the addition of chemicals.
However, this technique is time-consuming and repeatedly produces considerably wider
particle size of distribution. This type of production is based on atom-by-atom or molecule-
by-molecule arrangements in a well-programed manner, organized chemical reaction by both
liquid or gas phase, ensuring in nucleation and growth of nanoparticles. The bottom-up
process generates heavily clustered masses of particles that do not break up on reconstitution
[119]. Particles prepared by complex coacervation, salting-out, solvent emulsification diffu‐
sion, high-pressure homogenization, nanoprecipitation, supercritical fluid, co-precipitation,
rapid expansion of supercritical solutions, supercritical antisolvent precipitation, and self-
assembly methods [119]. The nanoparticles used as carriers are polymeric nanoparticles,
magnetic nanoparticles, metal and inorganic nanoparticles, quantum dots, polymeric micelles
(PMs), solid lipid nanoparticles, and colloidal nanoliposomes.
7. Targeted Drug Delivery in Anticancer Therapy
A clear understanding of molecular mechanism of tumor proliferation, formation metastasis,
invasion, and angiogenesis ensures a new mechanistic basis for targeted tumor drug discovery
(targeted anticancer therapy). Exact blocking or altering of the molecular mechanism associ‐
ated in the pathogenesis of tumor cell proliferation by targeted chemotherapeutic agents
modify the natural process of the disease as well as improve therapeutic index with cytotoxic
agents. Anticancer drug for targeted delivery system must meet a few requirements: a) the
Figure 2. Schematic representation of SMART drug targeted strategies
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targeted drug must have minimal activity loss, b) it should destroy the targeted tumor cells,
c) must be well-regulated and predicate the active form of drug release [120], and d) leakage
of drug during transit must be minimal. Concurrently, therapeutic drugs with less dosage
should be used during targeted therapy (minimal dose than the normal chemotherapy) with
minimal side effects [120, 121]. Drugs are conjugated with nanocarriers and delivered to the
receptor (outside) or inside the targeted tumor cells by a selective targeting mechanism [121].
The previous traditional process of administration of chemotherapy is an aggregation of drugs
inside the tumor cells/tissues through EPR [122, 123, 117] as a result of the abnormal structure
of blood vessels closer to the tumor tissues. Thus, the drug discharges easily to the tissues near
the cancer cells [40, 123]. Furthermore, few drugs are used in conventional treatment such as
methotrexate [124], paclitaxel [125], doxorubicin [126], gemcitabine [127] hexamethylmela‐
mine [128], and cisplatin (DDP) or carboplatin (drugs based on platinum) [129]. The drug may
be delivered to: a) the capillary bed of the active site, b) specific type of cells, c) intracellular
region of tumour cells absent in normal healthy cells, and d) specific organ/tissues by com‐
plexion with the nanocarrier that recognizes the target. Conventional anticancer targeted
therapy is composed of ligands (receptor, antibodies, and chemotherapeutic drugs) conjugated
with nanocarriers, thus, the fabricated drug enables binding affinity with particular receptors
of the targeted cancer cells. Overexpression of receptors in cancer cells enhances the binding
affinity of the nanocarrier conjugated ligands to the receptor [121, 123, 117]. The targeted
delivery system discharges the chemotherapeutic drugs directly to tumor cells and maintains
prolonged circulation of the drugs with high concentration inside the tumor cells. However,
targeted drugs cannot be released back to the blood stream because of the ligand and receptor
binding affinity, the same principle that is used in immunogenicity [122].
8. Challenges and Future Directions
Smart drug targeted delivery system is approaching optimal therapeutic strategies for
malignant and other chronic diseases. Targeted drug delivery is a rather complex mechanism
that has many aspects that are far-fetched; however, it is an approach that has been successfully
used to treat cancer and other chronic diseases. An ideal delivery system of targeted drug
molecules to its specific tissue/cells/organs is still beyond our reach in many ways and still
poses a challenging task in the complex cellular network system of organisms. An ideal drug
targeted delivery system is the one that delivers the drug to the exact targeted tumor site in
the right dosage required [130]. The reality, however, is far away from the ideal scenario of
bench-to-bedside treatment. The dosage levels of drugs delivered to targets sites is much less
than 5% at most.
Our efforts must be motivated toward improving moderate drug dosages delivered to the
target sites. As chronic diseases and tumors may not be eradicated by just targeting one site,
it may also be necessary to concurrently aim at multiple targets. Consequently, it may be
worthwhile to develop a new technology or a “magic shotgun” strategy that distributes the
multiple drugs into multiple targets to achieve optimal therapy [130]. It will be a challenging
task to modify our current approaches on targeted drug delivery systems through such
alterations that will influence not only the strategies selected but also the approaches to
identify, modify, and test the success of these methodologies.
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Furthermore, clear validation for identifying new approaches and modifications, do not
basically lead to an improved outcomes without theatrical changes in our current protocols
on targeted drug delivery research to make significant improvements in the future. Advanced
nanomedicine technology-based drug delivery to the target sites will be limited by extrava‐
sation and blood circulation. However, selective ligand targets a tumor cell marker or receptor
through receptor-ligand binding that occurs only after delivery by extravasation and blood
circulation. The receptor-ligand communication will be problematic for tumors as cells “over-
express” targeted surface markers. The selective targeted surface marker will also be expressed
on the surface of the non-cancer cells due to the gross surplus of the cancer cell burden.
Relatively, over-dependence on nanoparticles alone will be inadequate for significant clinical
benefits. Improvement of targeted drug delivery systems will need better understanding of
various factors involved in the regulation of distribution in the blood, temporal heterogeneity,
tumor markers, energetic aspects of tumor spatial, and complexities of diffusional barriers in
solid tumors. In addition, we may not depend on a sole over-expressed tumor marker for
specific drug targeting therapeutic managements. Modern drug targeted delivery and its
methodologies are scientifically sound rationale with limited success mainly due to the
construction of nanomaterials and drugs according to biochemical and engineering principles
alone. The currently available nanoparticles can improve the blood circulation time and pave
the way into malignant cells by potentially modulating their ability to intermingle with tumor
cell receptors. These promising nanoparticles ensure problems such as the forceful modulation
of the malignant cells and cancer heterogeneity.
For malignant and other therapies, the ideal smart drug targeted delivery system delivers the
drug at a targeted tumor site. In the future, efforts must focus on exploring the delivery of
increased concentration of the drug to the targeted site. Malignant cells may not be eliminated
by just targeting one site, it may also be important to aim at multiple targets. Furthermore, in
the future, merging expertise in drug targeted delivery with technological improvements in
molecular medicine will pave the way to elucidate molecular and cellular mechanism under‐
lying diseases. New approaches under investigation should focus on "bench-to-bedside"
practices to reduce delay of therapeutic stages.
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